You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

CLARITIN HIVES RELIEF REDITAB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Claritin Hives Relief Reditab patents expire, and when can generic versions of Claritin Hives Relief Reditab launch?

Claritin Hives Relief Reditab is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in CLARITIN HIVES RELIEF REDITAB is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty-five suppliers are listed for this compound. Additional details are available on the loratadine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Claritin Hives Relief Reditab

A generic version of CLARITIN HIVES RELIEF REDITAB was approved as loratadine by PLD ACQUISITIONS LLC on January 21st, 2003.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CLARITIN HIVES RELIEF REDITAB?
  • What are the global sales for CLARITIN HIVES RELIEF REDITAB?
  • What is Average Wholesale Price for CLARITIN HIVES RELIEF REDITAB?
Summary for CLARITIN HIVES RELIEF REDITAB
Drug patent expirations by year for CLARITIN HIVES RELIEF REDITAB

US Patents and Regulatory Information for CLARITIN HIVES RELIEF REDITAB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc CLARITIN HIVES RELIEF REDITAB loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-003 Nov 19, 2003 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CLARITIN HIVES RELIEF REDITAB

See the table below for patents covering CLARITIN HIVES RELIEF REDITAB around the world.

Country Patent Number Title Estimated Expiration
South Africa 8603532 ⤷  Sign Up
Germany 10199025 ⤷  Sign Up
Cyprus 1129 PHARMACEUTICAL DOSAGE FORMS ⤷  Sign Up
World Intellectual Property Organization (WIPO) 8503707 ⤷  Sign Up
Switzerland 633717 Moulded carrier for chemicals and/or pharmaceuticals ⤷  Sign Up
Japan S5344619 PRODUCTION OF MOLDED ARTICLE CARRING CHEMICAL SUBSTANCE AND PACKAGED ARTICLE CONTAINING SAME ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CLARITIN HIVES RELIEF REDITAB

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1110543 SPC/GB08/005 United Kingdom ⤷  Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
0152897 C00152897/01 Switzerland ⤷  Sign Up FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0152897 SPC/GB01/012 United Kingdom ⤷  Sign Up PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
1110543 08C0004 France ⤷  Sign Up PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897 2001C/013 Belgium ⤷  Sign Up PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.